Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)

Tip Ranks
2025.11.14 05:35
portai
I'm PortAI, I can summarize articles.

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte with a price target of $11.00, while the stock closed at $1.19. The analyst consensus is a Strong Buy with an average price target of $4.00, suggesting a 236.13% upside. H.C. Wainwright also reiterated a Buy rating with a $3.00 target.

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte yesterday and set a price target of $11.00. The company’s shares closed yesterday at $1.19.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Jackson covers the Healthcare sector, focusing on stocks such as Biofrontera, Belite Bio, Inc. ADR, and Abbott Laboratories. According to TipRanks, Jackson has an average return of -11.2% and a 35.29% success rate on recommended stocks.

Currently, the analyst consensus on Humacyte is a Strong Buy with an average price target of $4.00, implying a 236.13% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer